137 related articles for article (PubMed ID: 22829886)
1. The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma.
Lautz TB; Jie C; Clark S; Naiditch JA; Jafari N; Qiu YY; Zheng X; Chu F; Madonna MB
PLoS One; 2012; 7(7):e40816. PubMed ID: 22829886
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB
J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics.
Zheng X; Naiditch J; Czurylo M; Jie C; Lautz T; Clark S; Jafari N; Qiu Y; Chu F; Madonna MB
Cell Death Dis; 2013 Jul; 4(7):e740. PubMed ID: 23887631
[TBL] [Abstract][Full Text] [Related]
4. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems.
More SS; Itsara M; Yang X; Geier EG; Tadano MK; Seo Y; Vanbrocklin HF; Weiss WA; Mueller S; Haas-Kogan DA; Dubois SG; Matthay KK; Giacomini KM
Clin Cancer Res; 2011 Apr; 17(8):2339-49. PubMed ID: 21421857
[TBL] [Abstract][Full Text] [Related]
5. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
6. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
7. Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53.
Huang JM; Sheard MA; Ji L; Sposto R; Keshelava N
Mol Cancer Ther; 2010 Dec; 9(12):3289-301. PubMed ID: 21159612
[TBL] [Abstract][Full Text] [Related]
8. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
Slovak ML; Hoeltge GA; Dalton WS; Trent JM
Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069
[TBL] [Abstract][Full Text] [Related]
10. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
[TBL] [Abstract][Full Text] [Related]
11. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
[TBL] [Abstract][Full Text] [Related]
12. Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells.
Morgan SS; Cranmer LD
BMC Res Notes; 2014 Nov; 7():812. PubMed ID: 25406429
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide functional genomic and transcriptomic analyses for genes regulating sensitivity to vorinostat.
Falkenberg KJ; Gould CM; Johnstone RW; Simpson KJ
Sci Data; 2014; 1():140017. PubMed ID: 25977774
[TBL] [Abstract][Full Text] [Related]
14. A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity.
Falkenberg KJ; Newbold A; Gould CM; Luu J; Trapani JA; Matthews GM; Simpson KJ; Johnstone RW
Cell Death Differ; 2016 Jul; 23(7):1209-18. PubMed ID: 26868908
[TBL] [Abstract][Full Text] [Related]
15. MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells.
Imesch P; Dedes KJ; Furlato M; Fink D; Fedier A
Int J Oncol; 2009 Sep; 35(3):631-40. PubMed ID: 19639184
[TBL] [Abstract][Full Text] [Related]
16. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
[TBL] [Abstract][Full Text] [Related]
17. Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.
Phillip CJ; Giardina CK; Bilir B; Cutler DJ; Lai YH; Kucuk O; Moreno CS
BMC Cancer; 2012 Apr; 12():145. PubMed ID: 22494660
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
Murahari S; Jalkanen AL; Kulp SK; Chen CS; Modiano JF; London CA; Kisseberth WC
BMC Cancer; 2017 Jan; 17(1):67. PubMed ID: 28109246
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cathepsin proteases attenuates migration and sensitizes aggressive N-Myc amplified human neuroblastoma cells to doxorubicin.
Gangoda L; Keerthikumar S; Fonseka P; Edgington LE; Ang CS; Ozcitti C; Bogyo M; Parker BS; Mathivanan S
Oncotarget; 2015 May; 6(13):11175-90. PubMed ID: 25883214
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal change and drug resistance in neuroblastoma.
Naiditch JA; Jie C; Lautz TB; Yu S; Clark S; Voronov D; Chu F; Madonna MB
J Surg Res; 2015 Jan; 193(1):279-88. PubMed ID: 25128389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
